• Hypertrophic cardiomyopathy. A condition in which the heart’s ability to pump blood is weakened because of enlargement, thickening or stiffening of the heart. While some individuals with hypertrophic cardiomyopathy are symptom-free, others experience dyspnea (shortness of breath), syncope (fainting) or angina (chest pain) that can progressively worsen. And there are those who are stricken with sudden cardiac death, regardless of the presence or absence of symptoms or even knowledge that one has the condition. According to the AHA, 36 percent of young athletes who die from sudden cardiac death have hypertrophic cardiomyopathy.

  • Dilated cardiomyopathy. Patients have an increased chance of developing serious arrhythmias (ventricular flutter/fibrillation) that lead to cardiac arrest

  • Wolff-Parkinson-White syndrome. A condition in which abnormal electrical pathways between the heart’s chambers cause the ventricles to receive abnormal signals, prompting a rapid and irregular heartbeat, when atrial fibrillation develops and the impulses travel into the ventricle at a very rapid rate through the accessory pathway.

  • Long QT syndrome. A disorder of the heart’s electrical system that may lead to a rapid heartbeat in times of stress, fear or anger, leading to fainting or cardiac arrest. Some medications can also induce this condition. In general, this condition is under-recognized and under-diagnosed. 

  • The Brugada syndrome. This is another genetic defect that can lead to sudden ventricular fibrillation. It is related to a mutation in the SCN5A gene. To diagnose this condition, cardiologists must carefully analyze electrocardiogram results. Genetic testing may also be required. A physician may also require electrocardiograms from family members if one of them have suffered from sudden cardiac arrest.